Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer.
- Author:
Hai-mei TIAN
1
;
Xiao-yan SHI
;
Jun FU
;
Dong-yan CHAO
;
Kai ZHANG
;
Ling-ying WU
;
Jin-wan WANG
;
Wei ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenosine Triphosphate; metabolism; Adult; Aged; Antineoplastic Agents; pharmacology; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma; drug therapy; pathology; Cisplatin; pharmacology; Cyclophosphamide; pharmacology; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; methods; Female; Humans; Luminescent Measurements; Middle Aged; Ovarian Neoplasms; drug therapy; pathology; Paclitaxel; pharmacology; Predictive Value of Tests; Sensitivity and Specificity
- From: Chinese Journal of Oncology 2005;27(5):296-298
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the correlation between results of ATP bioluminescence tumor chemosensitivity assay (ATP-TCA) of human ovarian cancer specimens in vitro and clinical chemo-therapeutic responses of patients.
METHODSThirty-four freshly taken ovarian cancer specimens (28 cases) and ascites (6 cases) and 9 chemotherapeutic drugs were tested in vitro for cancer chemosensitivity by ATP-TCA.
RESULTSAmong the 34 ovarian cancer cases, the efficacy of ATP-TCA is 94.0%, the sensitivity, the specificity, the positive and negative predicting values, and an overall predicting value in vitro and vivo were 90.0%, 91.7%, 94.7%, 84.6% and 90.6%, respectively.
CONCLUSIONThe results of ATP-TCA assay are correlated well with clinical treatment responses. The assay may be an important and useful method for individual-based chemotherapy of cancers.
